Global Tetanus Toxoid Vaccine Market is expected to reach $ 5.5 billion by the end of 2023, this market is projected to growing at a CAGR of ~ 5.3 % during 2017-2023.
Tetanus is an infectious disease caused by Clostridium tetani characterized by muscle spasms. The spasms may be very severe and even cause bone fractures. Other symptoms include fever, sweating, headache, trouble swallowing, hypertension etc. About 10% of those infected, die while a large number become incapacitated due to bone fractures. Tetanus toxoid vaccine is an inactive vaccine used to prevent tetanus by developing immunity against the pathogen causing tetanus. The general dosage recommendation is five doses during childhood, with a sixth given during adolescence with additional doses every 10 years. The tetanus vaccine was initially developed in 1924 and has resulted in a 95% decrease in the rate of tetanus in the US and is on the World Health Organization’s List of Essential Medicines. The vaccine also is considered very safe even during pregnancy and for those with HIV.
The market restraints of the tetanus toxoid vaccine are redness and pain at the site of injection, fever, and fatigue and muscles pains. Severe allergic reactions are the most serious side effects of the Tetanus toxoid vaccine which occur in less than one in 100,000 people. The market for tetanus toxoid vaccine is bipolar with contractual market having a sizable number of share as compared to the private market. The other market constraints include falling profitability of vaccine manufacturing, huge reduction of tetanus in the developed world which effectively eliminates the need for further vaccination due to herd immunity, side effects associated with vaccines, variability of efficacy of tetanus toxoid vaccine etc.
The low profitability in vaccine manufacturing has reduced incentives for developing vaccines for diseases of the developing world such as tuberculosis and malaria.
Get a Brochure of This Report @ https://www.marketresearchfuture.com/sample_request/5256 .
Key players of Global Tetanus toxoid vaccine market:
Key players profiled in the report are GlaxoSmithKline Plc., Merck & Co. Inc., Pfizer, Inc., Sanofi Pasteur, Inc., AstraZeneca Plc., Bharat Biotech, Shenzhen Kangtai Biological Products, Valeant Pharmaceuticals, Emergent Biosolutions Inc., Astellas Pharma Inc., Panacea Biotec and others.
US accounts for the maximum market share due to greater use of medications and greater expenditure on healthcare. The faster market uptake of new technology and devices in the US is also an important driver of the market for global Tetanus toxoid vaccine. Europe is the second largest market due to large disposable income and rising awareness. Asia Pacific region is expected to have the most future potential and it is estimated to be led by China and India. The Middle East & Africa market is led by the gulf nations particularly Saudi Arabia and UAE. The regions of Africa are expected to witness a moderate growth due to poor economic and political conditions and poor healthcare penetration.
1.2 scope of study
1.2.1 Research Objective
1.2.2 Assumptions & Limitations
1.3 Market Structure:
2 Research Methodology
2.1 Research Process:
2.2 Primary Research
2.3 Secondary Research:
Grab Attractive Discount on This Report @ https://www.marketresearchfuture.com/check-discount/5256 .
3 Market dynamics
3.4 Macroeconomic Indicators
4 Market factor analysis
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
+1 646 845 9312